News

The latest press releases, publications, and events for Innoviva Specialty Therapeutics

01.08.2026

Clinical efficacy and safety of eravacycline for the treatment of enterococcal infections: a subpopulation analysis

10.20.2025

Population pharmacokinetics (PPK) analysis of eravacycline (ERV) to support the dose selection for a trial in pediatric patients aged 8 to less than 18 years with complicated intra-abdominal infection (cIAI)

05.05.2025

Efficacy and safety of eravacycline versus tigecycline for complicated intra-abdominal infections in the ICU: a multicenter, single-blind, parallel randomized controlled trial study protocol

07.13.2024

The Surgical Infection Society Guidelines on the Management of Intra-Abdominal Infection: 2024 Update

06.24.2024

Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant Enterobacterales Isolates

06.24.2024

Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis

06.24.2024

Multicenter Clinical Evaluation of ETEST Eravacycline for Susceptibility Testing of Enterobacteriaceae and Enterococci

06.24.2024

Carbapenem-Resistant Klebsiella pneumoniae: Virulence Factors, Molecular Epidemiology and Latest Updates in Treatment Options

06.24.2024

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales

06.24.2024

In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates